药易购
(300937)
| 流通市值：14.16亿 | | | 总市值：20.88亿 |
| 流通股本：6486.42万 | | | 总股本：9566.67万 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,210,641,784.46 | 2,180,537,149.98 | 1,113,920,597 | 4,454,001,549.38 |
| 营业收入 | 3,210,641,784.46 | 2,180,537,149.98 | 1,113,920,597 | 4,454,001,549.38 |
| 二、营业总成本 | 3,226,558,054.83 | 2,180,631,623.37 | 1,099,524,353.69 | 4,420,627,855.76 |
| 营业成本 | 2,934,088,714.72 | 1,980,437,262.94 | 1,000,838,700.95 | 3,990,570,322.79 |
| 税金及附加 | 6,427,571.88 | 3,887,606.14 | 1,979,446.63 | 9,266,603.29 |
| 销售费用 | 214,329,247.99 | 148,052,933.56 | 73,889,959.27 | 324,125,373.26 |
| 管理费用 | 55,608,596.63 | 37,391,037.02 | 18,376,677.49 | 76,671,035.76 |
| 研发费用 | 9,280,034.18 | 6,295,049.06 | 2,518,249.71 | 10,721,084.94 |
| 财务费用 | 6,823,889.43 | 4,567,734.65 | 1,921,319.64 | 9,273,435.72 |
| 其中:利息费用 | 4,768,948.37 | 3,608,170.81 | 1,870,410.63 | 9,086,486.02 |
| 其中:利息收入 | 2,531,697.85 | 1,786,291.83 | 366,111.74 | 2,977,104.69 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | 0 |
| 加:投资收益 | -328,672.11 | 669,033.88 | 384,125.54 | 636,286.32 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | 279,722.3 | -14,694.39 | -2,770.27 | -9,311.77 |
| 资产减值损失(新) | -6,160,963.69 | -1,057,145.8 | -509,664.61 | -9,913,533.42 |
| 信用减值损失(新) | -14,090,184.22 | -15,545,200.75 | -11,717,520.22 | -15,786,693.6 |
| 其他收益 | 3,654,661.8 | 3,183,984.26 | 293,356.09 | 2,113,891.93 |
| 四、营业利润 | -32,561,706.29 | -12,858,496.19 | 2,843,769.84 | 10,414,333.08 |
| 加:营业外收入 | 366,453.34 | 212,242.29 | 53,285.75 | 789,269.34 |
| 减:营业外支出 | 4,442,089.05 | 1,228,620.63 | 74,607.16 | 2,532,628.35 |
| 五、利润总额 | -36,637,342 | -13,874,874.53 | 2,822,448.43 | 8,670,974.07 |
| 减:所得税费用 | -208,821.21 | 1,072,728.35 | 1,638,836.28 | 23,719,394 |
| 六、净利润 | -36,428,520.79 | -14,947,602.88 | 1,183,612.15 | -15,048,419.93 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -36,428,520.79 | -14,947,602.88 | 1,183,612.15 | -15,048,419.93 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -23,418,865.41 | -10,530,483.26 | -2,720,169.6 | -11,170,934.57 |
| 少数股东损益 | -13,009,655.38 | -4,417,119.62 | 3,903,781.75 | -3,877,485.36 |
| 扣除非经常损益后的净利润 | -23,642,847.51 | -11,588,107.18 | -3,084,111.65 | -12,621,459.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.24 | -0.11 | -0.03 | -0.12 |
| (二)稀释每股收益 | -0.24 | -0.11 | -0.03 | -0.12 |
| 九、综合收益总额 | -36,428,520.79 | -14,947,602.88 | 1,183,612.15 | -15,048,419.93 |
| 归属于母公司股东的综合收益总额 | -23,418,865.41 | -10,530,483.26 | -2,720,169.6 | -11,170,934.57 |
| 归属于少数股东的综合收益总额 | -13,009,655.38 | -4,417,119.62 | 3,903,781.75 | -3,877,485.36 |
| 公告日期 | 2026-10-30 | 2026-08-25 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 保留意见 |